Clinical Trial Update: A Study of Navenibart in Participants With Hereditary Angioedema [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate the safety and efficacy of Navenibart in participants with hereditary angioedema; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Navenibart

Snippet

Sponsor: Astria Therapeutics, Inc. | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: RECRUITING